Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

F. Pietrantonio1* M. C. Garassino1 V. Torri2 and F. de Braud1

首页> 外文期刊>Annals of Oncology >Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

【24h】

Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

机译：答复FOLFIRI加西妥昔单抗与FOLFIRI加贝伐单抗作为转移性结直肠癌患者的一线治疗–德国AIO随机研究KRK-0306中KRAS突变肿瘤患者的亚组分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Annals of Oncology》 |2012年第10期|p.2771-2772|共2页
作者
F. Pietrantonio1* M. C. Garassino1 V. Torri2 and F. de Braud1;
展开▼
作者单位

1Medical Oncology Unit 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 2Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306 [J] . PietrantonioF., GarassinoM.C., TorriV., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第10期

机译：答复德国AIO随机研究KRK-0306中FOLFIRI加西妥昔单抗与FOLFIRI加贝伐单抗作为转移性结直肠癌患者一线治疗的KRAS突变肿瘤患者亚组分析
2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: Mutated tumours in the randomised German AIO study KRK-0306 [J] . StintzingS., FischervonweikersthalL., DeckerT., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第7期

机译：FOLFIRI加西妥昔单抗与FOLFIRI加贝伐单抗作为转移性结直肠癌患者一线治疗的KRAS患者亚组分析：德国AIO随机研究KRK-0306中的突变肿瘤
3. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306 [J] . S. Stintzing1 L. Fischer von Weikersthal2 T. Decker3 U. Vehling-Kaiser4 E. Jäger5 T. Heintges6 C. Stoll7 C. Giessen1 D. P. Modest1 J. Neumann8 A. Jung8 T. Kirchner8 W. Scheithauer9 and V. Heinemann1* Annals of Oncology . 2012,第7期

机译：FOLFIRI加西妥昔单抗与FOLFIRI加贝伐单抗作为转移性结直肠癌患者的一线治疗– KRAS患者亚组分析：德国AIO随机研究KRK-0306中的突变肿瘤
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Comparative Analysis on Innate Immune System Function in Metastatic Breast, Colorectal, and Prostate Cancer Patients with Circulating Tumor Cells [D] . Santos, Mark Anthony Francisco. 2014

机译：转移性乳腺癌，结直肠癌和前列腺癌患者循环肿瘤细胞先天免疫系统功能的比较分析
6. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis [O] . Dimitrios Pectasides, George Papaxoinis, Konstantine T Kalogeras, 2012

机译：XELIRI-贝伐单抗与FOLFIRI-贝伐单抗作为转移性结直肠癌患者的一线治疗：一项具有并行生物标志物分析的希腊合作肿瘤小组III期临床试验
7. PCN66 A Cost and Outcomes Analysis of Bevacizumab plus Folfiri Versus Cetuximab Plus Folfiri for the Treatment of First-Line Metastatic Colorrectal Cancer Patients from the Brazilian Private Payer Perspective [O] . R. Caponero, E.A.V. Santos, C.T. Buschinelli, 2011

机译：PCN66贝伐单抗Plus Folfiri对Cetuximab Plus Folfiri的成本和结果分析，用于从巴西私人付款人的临时术语治疗一线转移性菌血病患者

Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

著录项

引文网络

相似文献

相关主题

期刊订阅